A low molecular weight dextran sulphate, ILB(R), for the treatment of amyotrophic lateral sclerosis (ALS): an open-label, single-arm, single-centre, phase II trial https://www.medrxiv.org/content/10.1101/2023.08.27.23294691
QOTO: Question Others to Teach Ourselves An inclusive, Academic Freedom, instance All cultures welcome. Hate speech and harassment strictly forbidden.